AX 208
Alternative Names: AX208Latest Information Update: 19 Mar 2009
At a glance
- Originator SYGNIS Bioscience GmbH
- Class Amino acids; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma; Huntington's disease; Parkinson's disease
Most Recent Events
- 30 Apr 2007 Preclinical trials in Glaucoma in Germany (unspecified route)
- 30 Apr 2007 Preclinical trials in Huntington's disease in Germany (unspecified route)
- 30 Apr 2007 Preclinical trials in Parkinson's disease in Germany (unspecified route)